Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,941 to 3,960 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| 17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Fetal/Early Infant Death | 19 of 1,130 11 of 578 | -0.2 points -1.8 to 1.0 | 1,708 | NCT01004029 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery |
| 17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 37 Weeks Gestation | 257 of 1,130 125 of 578 | 1.1 points -3.1 to 5.2 | 1,708 | NCT01004029 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery |
| 17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 32 Weeks Gestation | 54 of 1,130 30 of 578 | -0.4 points -2.8 to 1.7 | 1,708 | NCT01004029 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery |
| Pooled 20vPnC vs 13vPnC: serious adverse events | 10 of 1,463 0 of 245 | 0.7 points -0.9 to 1.3 | 1,708 | NCT03828617 Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults |
| 17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: serious adverse events | 34 of 1,128 18 of 578 | -0.1 points -2.0 to 1.5 | 1,706 | NCT01004029 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants With Non Fatal Myocardial Infarction | 35 of 877 37 of 828 | -0.5 points -2.4 to 1.5 | 1,705 | NCT01499511 Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study |
| Pre-intervention Group vs Intervention Group: Number of Patients That Die During the Hospitalization | 338 of 1,192 105 of 513 | 7.9 points 3.4 to 12.1 | 1,705 | NCT02543554 ED Lung Protective Ventilation to Reduce Complications |
| Pre-intervention Group vs Intervention Group: Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department | 171 of 1,192 38 of 513 | 6.9 points 3.7 to 9.8 | 1,705 | NCT02543554 ED Lung Protective Ventilation to Reduce Complications |
| Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With Elevated Temperature (>=102.2F/39.0C) | 56 of 1,383 13 of 320 | -0.0 points -2.9 to 2.0 | 1,703 | NCT00326183 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) |
| Normal Saline vs Magnesium Sulfate: Modified Rankin Score ≤2 | 445 of 843 449 of 857 | 0.4 points -4.3 to 5.1 | 1,700 | NCT00059332 Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial |
| Normal Saline vs Magnesium Sulfate: Mortality | 131 of 843 132 of 857 | 0.1 points -3.3 to 3.6 | 1,700 | NCT00059332 Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial |
| Normal Saline vs Magnesium Sulfate: Symptomatic Intracranial Hemorrhage | 28 of 843 18 of 857 | 1.2 points -0.3 to 2.9 | 1,700 | NCT00059332 Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial |
| Normal Saline vs Magnesium Sulfate: Serious Adverse Events | 422 of 843 439 of 857 | -1.2 points -5.9 to 3.6 | 1,700 | NCT00059332 Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial |
| Normal Saline vs Magnesium Sulfate: Modified Rankin Score of 0 or 1 | 311 of 843 313 of 857 | 0.4 points -4.2 to 4.9 | 1,700 | NCT00059332 Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial |
| Normal Saline vs Magnesium Sulfate: serious adverse events | 422 of 843 439 of 857 | -1.2 points -5.9 to 3.6 | 1,700 | NCT00059332 Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial |
| With Suicidal Ideation (Including Suicide Attempt) vs Without Suicidal Ideation (Including Suicide Attempt): Factors Considered to Affect the Efficacy of Sertraline: Suicidal Ideation (Including Suicide Attempt) | 319 of 397 1,136 of 1,303 | -6.8 points -11.4 to -2.7 | 1,700 | NCT00605865 Drug Use Investigation of Jzoloft. |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial | 10 of 874 9 of 826 | 0.1 points -1.0 to 1.1 | 1,700 | NCT01499511 Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack) | 29 of 877 52 of 823 | -3.0 points -5.1 to -1.0 | 1,700 | NCT01499511 Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study |
| Bexagliflozin Tablets, 20 mg vs Placebo Tablets: deaths from any cause | 39 of 1,132 26 of 567 | -1.1 points -3.4 to 0.8 | 1,699 | NCT02558296 Bexagliflozin Efficacy and Safety Trial |
| Bexagliflozin Tablets, 20 mg vs Placebo Tablets: serious adverse events | 373 of 1,132 208 of 567 | -3.7 points -8.6 to 1.0 | 1,699 | NCT02558296 Bexagliflozin Efficacy and Safety Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=198"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=198
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01004029-7fed5651",
"title": "17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Fetal/Early Infant Death",
"summary": "19 of 1130 against 11 of 578; risk difference -0.2 points, 95% interval -1.8 to 1.0; NCT01004029, Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery",
"record": "/library/comparisons/NCT01004029-7fed5651",
"nct_id": "NCT01004029",
"kind": "outcome",
"participants": 1708,
"risk_difference": {
"value": -0.002216982576476713,
"lower": -0.01812443077334891,
"upper": 0.01029454516455793
},
"group_1": "19 of 1,130",
"group_2": "11 of 578",
"difference": "-0.2 points",
"interval": "-1.8 to 1.0",
"trial_title": "Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery"
},
{
"id": "NCT01004029-b040dc89",
"title": "17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 37 Weeks Gestation",
"summary": "257 of 1130 against 125 of 578; risk difference 1.1 points, 95% interval -3.1 to 5.2; NCT01004029, Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery",
"record": "/library/comparisons/NCT01004029-b040dc89",
"nct_id": "NCT01004029",
"kind": "outcome",
"participants": 1708,
"risk_difference": {
"value": 0.011170652540037351,
"lower": -0.03129687657286433,
"upper": 0.05169996060033175
},
"group_1": "257 of 1,130",
"group_2": "125 of 578",
"difference": "1.1 points",
"interval": "-3.1 to 5.2",
"trial_title": "Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=199",
"request_id": "evbRV8oCTHXmVWOf"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant